company background image

Cipher Pharmaceuticals TSX:CPH Stock Report

Last Price


Market Cap







17 Aug, 2022


Company Financials +
CPH fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance3/6
Financial Health6/6

CPH Stock Overview

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.

Cipher Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cipher Pharmaceuticals
Historical stock prices
Current Share PriceCA$2.43
52 Week HighCA$2.80
52 Week LowCA$1.54
1 Month Change10.96%
3 Month Change1.67%
1 Year Change23.35%
3 Year Change94.40%
5 Year Change-50.41%
Change since IPO-34.32%

Recent News & Updates

May 14
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

CPHCA PharmaceuticalsCA Market

Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned -61.8% over the past year.

Return vs Market: CPH exceeded the Canadian Market which returned 2.1% over the past year.

Price Volatility

Is CPH's price volatile compared to industry and market?
CPH volatility
CPH Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement12.3%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.2%

Stable Share Price: CPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CPH's weekly volatility (4%) has been stable over the past year.

About the Company

20005Craig Mull

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company’s licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Cipher Pharmaceuticals Inc. Fundamentals Summary

How do Cipher Pharmaceuticals's earnings and revenue compare to its market cap?
CPH fundamental statistics
Market CapCA$60.98m
Earnings (TTM)CA$10.21m
Revenue (TTM)CA$27.58m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CPH income statement (TTM)
Cost of RevenueUS$3.92m
Gross ProfitUS$17.42m
Other ExpensesUS$9.52m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)0.31
Gross Margin81.64%
Net Profit Margin37.04%
Debt/Equity Ratio0%

How did CPH perform over the long term?

See historical performance and comparison